Adicet Bio/ACET

$2.10

5%
-
1D1W1MYTD1YMAX

About Adicet Bio

Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Ticker

ACET

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Chen Schor

Employees

143

Headquarters

Boston, United States

Adicet Bio Metrics

BasicAdvanced
$160.2M
Market cap
-
P/E ratio
-$3.32
EPS
1.88
Beta
-
Dividend rate
$160.2M
1.8797
$7.50
$1.10
1.45M
8.414
-53.03%
-61.69%
-57.18%
0.496
0.941
-100%
-96.26%

What the Analysts think about Adicet Bio

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 6 analysts.
328.57% upside
High $19.00
Low $5.00
$2.10
Current price
$9.00
Average price target

Adicet Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-29.4M
-40.96%
Profit margin
0%
-

Adicet Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.65%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.72
-$0.75
-$1.16
-$0.69
-
Expected
-$0.69
-$0.68
-$0.74
-$0.69
-$0.39
Surprise
4.76%
10.04%
57.33%
-0.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Adicet Bio stock?

Adicet Bio (ACET) has a market cap of $160.2M as of April 23, 2024.

What is the P/E ratio for Adicet Bio stock?

The price to earnings (P/E) ratio for Adicet Bio (ACET) stock is 0 as of April 23, 2024.

Does Adicet Bio stock pay dividends?

No, Adicet Bio (ACET) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Adicet Bio dividend payment date?

Adicet Bio (ACET) stock does not pay dividends to its shareholders.

What is the beta indicator for Adicet Bio?

Adicet Bio (ACET) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Adicet Bio stock price target?

The target price for Adicet Bio (ACET) stock is $9, which is 328.57% above the current price of $2.1. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Adicet Bio stock

Buy or sell Adicet Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing